RT Journal Article
T1 Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry.
A1 Núñez-Gil, Iván J
A1 Olier, Iván
A1 Feltes, Gisela
A1 Viana-Llamas, María C
A1 Maroun-Eid, Charbel
A1 Romero, Rodolfo
A1 Fernández-Rozas, Inmaculada
A1 Uribarri, Aitor
A1 Becerra-Muñoz, Victor M
A1 Alfonso-Rodriguez, Emilio
A1 García-Aguado, Marcos
A1 Elola, Javier
A1 Castro-Mejía, Alex
A1 Pepe, Martino
A1 Garcia-Prieto, Juan Fortunato
A1 Gonzalez, Adelina
A1 Ugo, Fabrizio
A1 Cerrato, Enrico
A1 Bondia, Elvira
A1 Raposeiras-Roubin, Sergio
A1 Mendez, Jorge L Jativa
A1 Espejo, Carolina
A1 López-Masjuan, Álvaro
A1 Marin, Francisco
A1 López-Pais, Javier
A1 Abumayyaleh, Mohammad
A1 Corbi-Pascual, Miguel
A1 Liebetrau, Christoph
A1 Ramakrishna, Harish
A1 Estrada, Vicente
A1 Macaya, Carlos
A1 Fernandez-Ortiz, Antonio
A1 HOPE COVID-19 Investigators (Cols Appendix), 
AB The use of Renin-Angiotensin system inhibitors (RASi) in patients with coronavirus disease 2019 (COVID-19) has been questioned because both share a target receptor site. HOPE-COVID-19 (NCT04334291) is an international investigator-initiated registry. Patients are eligible when discharged after an in-hospital stay with COVID-19, dead or alive. Here, we analyze the impact of previous and continued in-hospital treatment with RASi in all-cause mortality and the development of in-stay complications. We included 6503 patients, over 18 years, from Spain and Italy with data on their RASi status. Of those, 36.8% were receiving any RASi before admission. RASi patients were older, more frequently male, with more comorbidities and frailer. Their probability of death and ICU admission was higher. However, after adjustment, these differences disappeared. Regarding RASi in-hospital use, those who continued the treatment were younger, with balanced comorbidities but with less severe COVID19. Raw mortality and secondary events were less frequent in RASi. After adjustment, patients receiving RASi still presented significantly better outcomes, with less mortality, ICU admissions, respiratory insufficiency, need for mechanical ventilation or prone, sepsis, SIRS and renal failure (p RASi historic use, at admission, is not related to an adjusted worse prognosis in hospitalized COVID-19 patients, although it points out a high-risk population. In this setting, the in-hospital prescription of RASi is associated with improved survival and fewer short-term complications.
YR 2021
FD 2021-04-15
LK http://hdl.handle.net/10668/17565
UL http://hdl.handle.net/10668/17565
LA en
DS RISalud
RD Apr 10, 2025